ArticleScientific reports2016
Microfluidic enrichment for the single cell analysis of circulating tumor cells.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 123 citations in OpenAlex.
- Integrated microfluidic biosensors: shaping the future of quantitative life sciences and on-chip molecular diagnostics.Lab on a chip · 2026Review
- Controlling fluid flow rate to separate leukocytes and cancer cells based on stiffness differences.Mikrochimica acta · 2025Article
- Exosomal mRNA Cargo are biomarkers of tumor and immune cell populations in pediatric osteosarcoma.Translational oncology · 2024Article
- EchoGrid: High-Throughput Acoustic Trapping for Enrichment of Environmental Microplastics.Analytical chemistry · 2024Article
- Novel Isolating Approaches to Circulating Tumor Cell Enrichment Based on Microfluidics: A Review.Micromachines · 2024Review
- Deciphering cellular complexity: advances and future directions in single-cell protein analysis.Frontiers in bioengineering and biotechnology · 2024Review
- On-chip modeling of tumor evolution: Advances, challenges and opportunities.Materials today. Bio · 2023Review
- Dielectrophoresis-Based Selective Droplet Extraction Microfluidic Device for Single-Cell Analysis.Micromachines · 2023Article
- Modular microfluidics for life sciences.Journal of nanobiotechnology · 2023Review
- Unraveling Cancer Metastatic Cascade Using Microfluidics-based Technologies.Biophysical reviews · 2022Review
- Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse.Frontiers in oncology · 2022Article
- Nanomaterial-Based Immunocapture Platforms for the Recognition, Isolation, and Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Microfluidic technology for multiple single-cell capture.Biomicrofluidics · 2021Review
- Article
- Biomaterials by design: Harnessing data for future development.Materials today. Bio · 2021Review
- High-Throughput Cell Trapping in the Dentate Spiral Microfluidic Channel.Micromachines · 2021Article
- Inertial Microfluidics Enabling Clinical Research.Micromachines · 2021Review
- Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer.Frontiers in oncology · 2021Article
- Past, Present, and Future of Affinity-based Cell Separation Technologies.Acta biomaterialia · 2020Review
- Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal.Journal of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to drug therapy is a major concern in cancer treatment. To probe clones resistant to chemotherapy, the current approach is to conduct pooled cell analysis. However, this can yield false negative outcomes, especially when we are analyzing a rare number of circulating tumor cells (CTCs) among an abundance of other cell types. Here, we develop a microfluidic device that is able to perform high throughput, selective picking and isolation of single CTC to 100% purity from a larger population of other cells. This microfluidic device can effectively separate the very rare CTCs from blood samples from as few as 1 in 20,000 white blood cells. We first demonstrate isolation of pure tumor cells from a mixed population and track variations of acquired T790M mutations before and after drug treatment using a model PC9 cell line. With clinical CTC samples, we then show that the isolated single CTCs are representative of dominant EGFR mutations such as T790M and L858R found in the primary tumor. With this single cell recovery device, we can potentially implement personalized treatment not only through detecting genetic aberrations at the single cell level, but also through tracking such changes during an anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.